202 related articles for article (PubMed ID: 29193395)
1. Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.
Ravaioli S; Tumedei MM; Foca F; Maltoni R; Rocca A; Massa I; Pietri E; Bravaccini S
Int J Exp Pathol; 2017 Oct; 98(5):289-295. PubMed ID: 29193395
[TBL] [Abstract][Full Text] [Related]
2. Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.
Tumedei MM; Silvestrini R; Ravaioli S; Massa I; Maltoni R; Rocca A; Folli S; Buggi F; Curcio A; Serra L; Puccetti M; Amadori D; Bravaccini S
Int J Biol Markers; 2015 Nov; 30(4):e425-8. PubMed ID: 26165687
[TBL] [Abstract][Full Text] [Related]
3. Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment?
Ravaioli S; Puccetti M; Tumedei MM; Silvestrini R; Bedei L; Bravaccini S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):301-305. PubMed ID: 28968271
[TBL] [Abstract][Full Text] [Related]
4. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
5. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical categorisation of ductal carcinoma in situ of the breast.
Meijnen P; Peterse JL; Antonini N; Rutgers EJ; van de Vijver MJ
Br J Cancer; 2008 Jan; 98(1):137-42. PubMed ID: 18043578
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors.
Selim AG; El-Ayat G; Wells CA
J Clin Pathol; 2002 Jan; 55(1):14-6. PubMed ID: 11825917
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ: a disease entity that merits more recognition.
Dereere E; Papadimitriou K; Tjalma W; Altintas S
Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
[TBL] [Abstract][Full Text] [Related]
12. Expression of androgen receptor in breast cancer and its significance as a prognostic factor.
Yu Q; Niu Y; Liu N; Zhang JZ; Liu TJ; Zhang RJ; Wang SL; Ding XM; Xiao XQ
Ann Oncol; 2011 Jun; 22(6):1288-1294. PubMed ID: 21109569
[TBL] [Abstract][Full Text] [Related]
13. The Relationships between HER2 Overexpression and DCIS Characteristics.
Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
[TBL] [Abstract][Full Text] [Related]
14. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
15. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor.
Rody A; Diallo R; Poremba C; Wuelfing P; Kissler S; Solbach C; Kaufmann M; Jackisch C
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):25-9. PubMed ID: 15722790
[TBL] [Abstract][Full Text] [Related]
17. Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS).
Cheung S; Booth ME; Kearins O; Dodwell D
Breast; 2014 Dec; 23(6):807-11. PubMed ID: 25270228
[TBL] [Abstract][Full Text] [Related]
18. Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.
Martínez-Pérez C; Turnbull AK; Ekatah GE; Arthur LM; Sims AH; Thomas JS; Dixon JM
Cancer Treat Rev; 2017 Apr; 55():163-172. PubMed ID: 28402908
[TBL] [Abstract][Full Text] [Related]
19. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
20. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
